Clinical Trials Browser

INDUSTRY × Interventional × Acrocephalosyndactylia × Clear all

NCT05567185 2026-03-13

TAR-210

Phase 1 Active not recruiting

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Phase 1 Active not recruiting

Acrocephalosyndactylia, Breast Neoplasms

NCT04238715 2026-03-02

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Phase 2 Completed

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase 2 Terminated

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03144661 2025-10-21

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Phase 1 Terminated

GastrointestinalGynecologicHead & Neck

Acrocephalosyndactylia, Esophageal Neoplasms, Carcinoma, Hepatocellular, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 2 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Phase 2 Completed

8 enrolled 13 charts

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase 2 Completed

GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma

NCT01703481 2025-02-03

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Phase 1 Completed

LymphoidThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasms, Small Cell Lung Carcinoma

NCT04604132 2024-04-04

FIDES-03

Phase 1/2 Terminated

47 enrolled 22 charts

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT04045613 2023-10-13

FIDES-02

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05019794 2022-06-27

FGFR

Phase 2 Unknown

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase 1 Completed

Acrocephalosyndactylia, Breast Neoplasms

NCT03235570 2020-05-29

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Phase 1 Completed

Acrocephalosyndactylia, Neoplasms